首页> 外文期刊>Clinical microbiology and infection: European Society of Clinical Microbiology and Infectious Diseases >Clinical and microbiologic characteristics of adult patients with recurrent bacteraemia caused by extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella pneumoniae
【24h】

Clinical and microbiologic characteristics of adult patients with recurrent bacteraemia caused by extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella pneumoniae

机译:延伸β-内酰胺酶的临床和微生物特征延长β-内酰胺酶大肠杆菌或克雷布氏菌肺炎

获取原文
获取原文并翻译 | 示例
           

摘要

The characteristics of patients with recurrent bacteraemia caused by extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli or Klebsiella pneumoniae (EK) are rarely described. Flomoxef belongs to the cephamycins group and demonstrates in vitro activity against ESBL-producing organisms. Whether flomoxef may be used for the treatment of such infections remains controversial. This retrospective case-control study enrolled adult patients who had bacteraemia caused by ESBL-EK during 2005-2011. Case patients were those who had more than one episode of ESBL-EK bacteraemia. Controls were those who were matched for age and interval time of blood sampling and had only one episode of ESBL-EK bacteraemia with subsequent bacteraemia episodes caused by other non-ESBL-EK bacteria. Pulsed-field gel electrophoresis and microbiologic profiles of the initial and subsequent ESBL-EK isolates were analysed. During the study period, 424 patients were found to have at least one positive blood culture after the first ESBL-EK bacteraemia episode, and 67 (15.8%) had a second episode of ESBL-EK bacteraemia. Bacteraemia resulting from vascular catheter-related infection (odds ratio, 3.24; 95% confidence interval, 1.31-8.05), and definitive therapy with flomoxef (odds ratio, 2.99; 95% confidence interval, 1.10-8.15) were both independent risk factors for the recurrence. Among the 56 patients with available ESBL-EK isolates for analysis, 38 (67.8%) were infected by genetically similar strains. In three of these 38 recurrent ESBL-EK bacteraemia cases caused by an identical strain, the minimum inhibitory concentrations of carbapenem for the subsequent K. pneumoniae isolates were fourfold or higher than the initial isolates. Recurrent bacteraemia was not uncommon in our patients with ESBL-EK bacteraemia, and most of the episodes were caused by identical strains. Clinical Microbiology and Infection (C) 2015 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
机译:很少描述由扩展β-内酰胺酶(ESBL)引起的复发性菌血症患者的特征很少描述。 Flomoxef属于Cephamycins组,并证明了对产生ESBL-生物体的体外活动。 Flomoxef是否可用于治疗此类感染仍然存在争议。这种回顾性案例对照研究注册了2005 - 2011年期间eSBL-ek引起的菌细菌的成年患者。病例患者是患有ESBL-EK菌血症的一集的人。对照是那些与年龄和血液取样的间隔时间相匹配的人,并且只有一集ESBL-ek菌血症,其其他非ESBL-EK细菌引起的后续菌细菌发作。分析了突出场凝胶电泳和初始和随后的ESBL-EK分离株的微生物谱。在研究期间,在第一个ESBL-EK菌血症发作后发现424名患者至少有一个正血液培养,67(15.8%)有ESBL-EK菌血症的第二集。受血管导管相关感染的菌血症(差距为3.24; 95%; 95%置信区间,1.31-8.05)和氟氧氟丝的最终疗法(差距比,2.99; 95%置信区间,1.10-8.15)都是独立的风险因素复发。在56名可用ESBL-EK分离株的患者中,通过遗传相似的菌株感染38例(67.8%)。在这38个复发性ESBL-EK菌株中的三种菌株中的三种菌株中,随后的K.肺癌的最小抑制浓度为肺炎群分离物为四倍或高于初始分离物。在我们的ESBL-ek菌血症患者中,复发性菌血症在患者中并不少见,大部分发作是由相同的菌株引起的。临床微生物学与感染2015年欧洲临床微生物学与传染病学会。 elsevier有限公司出版。保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号